MPR for Stroke Risk Assessment of ICAS
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Standardized medical therapy targeting vascular risk factors and stroke prevention.
- Who it may be relevant to
- Registry conditions: ICAS - Intracranial Atherosclerosis, Stroke Ischemic, Hemodynamic. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
MRI-Derived Pressure Ratio: a Novel Noninvasive Hemodynamic Biomarker for Stroke Risk Stratification in Intracranial Atherosclerotic Stenosis
Overview
Intracranial atherosclerotic stenosis (ICAS) carries substantial stroke risk despite optimal medical treatment. Current risk stratification relies primarily on stenosis severity, but novel hemodynamic markers may improve prediction. In this multiple prospective registry study we aim to investigate whether regional hemodynamics, measured by a novel Magnetic resonance imaging-derived Pressure Ratio (MPR) technique, are associated with stroke risk in ICAS.
Detailed description
This study is a multicentre prospective single-arm registry study and the protocol is approved by the ethics committee at the coordinating centre and by the local institutional review board at each participating centre. This study is initiated by the investigators, with 5 participating stroke centres , and plans to recruit 400 consecutive patients who meet the inclusion and exclusion criteria. After the enrolment, all participants would be evaluated at baseline, 1 month, 6 months, and 12 months post-enrollment. All participants received standardized medical therapy, including dual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines. Multimodal imaging techniques were employed to assess hemodynamic status: luminal stenosis would be evaluated using transcranial Doppler (TCD), computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA), high-resolution MRI and phase-contrast MR angiography (PC-MRA) would be collected to calculate MPR. The primary outcomes were ischemic stroke in the qualifying artery territory or related death within 1 year. There were 5 secondary outcomes, including hemodynamic ischemic stroke in the qualifying artery territory within1 year. An independent Data and Safety Monitoring Board (DSMB) oversees the conduction, safety and efficacy of the study.
Interventions
- Drug Standardized medical therapy targeting vascular risk factors and stroke prevention
Dual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines
Primary outcome measures
- ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment. [Time frame: 12 months]
Secondary outcome measures (5)
- transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year [Time frame: 12 months]
- TIA related to ischemia in the qualifying artery territory within 1 year [Time frame: 12 months]
- any stroke/TIA/ death within 1 year [Time frame: 12 months]
- hemodynamic ischemic stroke in the qualifying artery territory within 1 year [Time frame: 12 months]
- embolic stroke within in the qualifying artery territory 1 year [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Adults aged 18 to 80 years.
- Intracranial atherosclerotic stenosis ICAS involving a culprit artery in the anterior circulation.
- Intracranial arterial stenosis of 50% to 99% as measured by the WASID method using TCD, CTA, MRA, or DSA.
- Written informed consent obtained from the participant or a legal representative.
Exclusion criteria
- Non-atherosclerotic intracranial lesions, including moyamoya disease, vasculitis, vascular dissection, autoimmune diseases, or congenital/genetic abnormalities.
- More than 50% stenosis of the extracranial carotid artery on the ipsilateral side.
- Large cerebral infarction involving more than one-half of the territory on DWI imaging, or a baseline modified Rankin Scale score ≥3.
- Contraindications to antiplatelet therapy or statins.
- Inability to undergo MRI due to metal implants or claustrophobia.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Department of Neurosurgery, Xuanwu hospital — Beijing
Identifiers
NCT: NCT07309718 · CASSISS-MPR